Novo Nordisk Restructuring: Layoffs and the Fight for Market Share

Novo Nordisk, the maker of Wegovy, is slashing 9,000 jobs in a massive restructuring to save $1.26 billion annually. Facing fierce competition from rivals like Eli Lilly and copycat drugs, the company aims to streamline operations, speed up decision-making, and focus on high-growth areas like diabetes and obesity treatments. Will this bold move be enough for Novo Nordisk to maintain its market dominance? Hosted on Acast. See acast.com/privacy for more information.